AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $250.09. The company's market cap stands at 439.77B, with a P/E ratio of 72.51 and a dividend yield of 2.66%.
During the trading session on 2026-09-08, AbbVie(ABBV) shares reached a daily high of $254.62 and a low of $248.42. At a current price of $250.09, the stock is +0.7% higher than the low and still -1.8% under the high.
Trading activity shows a volume of 5.57M, compared to an average daily volume of 3.89M.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
ABBV News
Key Points Pharmaceutical giant AbbVie has a longer history of dividend growth than Pfizer. Pfizer faces greater exposure this decade to the loss of patent ex...
BofA raised the firm’s price target on AbbVie (ABBV) to $282 from $276 and keeps a Buy rating on the shares after updating the firm’s estimates to incorporate z...
Key Points AbbVie leverages a strong pipeline in immunology and oncology to drive nearly $61.2 billion in annual revenue. Pfizer maintains a diverse portfolio...
Analyst ratings
75%
of 32 ratingsMore ABBV News
AbbVie Inc. (NYSE:ABBV) on Thursday reported topline outcomes from its Phase 3 CERVINO trial evaluating etentamig, an investigational treatment for relapsed or...
(RTTNews) - AbbVie (ABBV) on Thursday announced positive topline results from the Phase 3 CERVINO trial evaluating investigational etentamig in patients with re...
AbbVie (ABBV) announced positive topline results from the Phase 3 Cervino study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, v...
AbbVie (ABBV) has completed its $10.9 billion acquisition of Apogee Therapeutics (APGE), the company said on Thursday. The deal, which is the pharma giant's la...
An update from AbbVie ( (ABBV) ) is now available. On Sept. 3, 2026, AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, adding late- and ea...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.